Silexion Therapeutics Corp (NASDAQ:SLXN) Sees Significant Decline in Short Interest

Silexion Therapeutics Corp (NASDAQ:SLXN) was the recipient of a significant decline in short interest in June. As of June 15th, there was short interest totaling 16,557 shares, a decline of 89.3% from the May 31st total of 154,973 shares. Based on an average daily trading volume, of 233,740 shares, the days-to-cover ratio is presently 0.1 days. Approximately 4.1% of the shares of the stock are sold short.

Silexion Therapeutics Price Performance

NASDAQ SLXN opened at $2.73 on Friday. Silexion Therapeutics has a 1-year low of $2.31 and a 1-year high of $223.60. The business has a 50 day simple moving average of $5.36 and a two-hundred day simple moving average of $13.93. The stock has a market capitalization of $1.15 million, a PE ratio of -0.03 and a beta of -0.32.

Silexion Therapeutics (NASDAQ:SLXN) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($12.90) by $12.05. On average, analysts anticipate that Silexion Therapeutics will post -45.5 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Monday, June 15th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.